Zai Lab Limited (ZLAB)
Develops cancer and immunology drugs for patients in China and globally
$18.72+0.00%Healthcare
StockGlow Score
Leaning Bullish
BearishBullish
1 year ago-49.2%
The outlook
ZLAB is trading near its 52-week lows with strong analyst backing—the consensus is a Strong Buy, with an average price target about 78% above the current price. The stock shows mixed momentum against its moving averages, reflecting recent weakness, though the overall sentiment leans bullish. Analyst coverage is solid at 12 firms.
What’s behind the score
Analyst consensusStrong Buy — 1.3 avg of 12 analysts
Price trendMixed vs its moving averages
52-week range11% of the way from its 52-week low to high
Price targetAvg target +78% vs current price
Analyst price target
~12-month · 12 analysts$33.30average target+77.9% vs now
Now $18.72
Low $21.60High $52.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$2.11B
52-wk high
$41.20
52-wk low
$15.96
50-day avg
$18.71
200-day avg
$20.21
Trailing P/E
—